AR060506A1 - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
AR060506A1
AR060506A1 ARP070101533A ARP070101533A AR060506A1 AR 060506 A1 AR060506 A1 AR 060506A1 AR P070101533 A ARP070101533 A AR P070101533A AR P070101533 A ARP070101533 A AR P070101533A AR 060506 A1 AR060506 A1 AR 060506A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
alkyl
formula
halogen
compound
Prior art date
Application number
ARP070101533A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0607532A external-priority patent/GB0607532D0/en
Priority claimed from GB0610244A external-priority patent/GB0610244D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR060506A1 publication Critical patent/AR060506A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un proceso para la preparacion de compuestos de la Formula (1) o un solvato o hidrato de los mismos, en donde: R es fenilo que está insustituido o que está sustituido por 1, 2, o 3 sustituyentes seleccionados a partir del grupo que consiste en halogeno, alquilo de 1 a 7 átomos de carbono, trifluoro-metilo, hidroxilo, y alcoxilo de 1 a 7 átomos de carbono; R1 es hidrogeno o alquilo de 1 a 7 átomos de carbono; R2 es hidrogeno, alquilo de 1 a 7 átomos de carbono, o fenilo que está insustituido o que está sustituido por 1, 2, o 3 sustituyentes seleccionados a partir del grupo que consiste en halogeno, alquilo de 1 a 7 átomos de carbono, trifluoro-metilo, hidroxilo, y alcoxilo de 1 a 7 átomos de carbono; R3 es fenilo que está insustituido o que está sustituido por 1, 2, o 3 sustituyentes seleccionados a partir del grupo que consiste en halogeno, alquilo de 1 a 7 átomos de carbono, trifluoro-metilo, hidroxilo, y alcoxilo de 1 a 7 átomos de carbono, o r3 es nftilo, 1H- indol-3-ilo, o 1-alquilo de 1 a 7 átomos de carbono-indol-3-ilo, y R5 eds cicloalquilo de 3 a 8 átomos de carbono, D-azacicloheptan-2-on-3-ilo o L-aza-cicloheptan-2-on-3-ilo, comprendiendo el proceso los pasos de: (a) Hacer reaccionar un compuesto de la Formula (2) en donde R1, R2, R3, y R5 son como se definen en esta reivindicacion anteriormente, y T es un grupo protector, con una base, para formar un compuesto de la Formula (3); en donde R1, R2, R3, R5 son como se definen en esta reivindicacion anteriormente; y (b) hacer reaccionar un compuesto de la Formula ll. como R1, R2, R3, y R5 son como se definen en esta reivindicacion anteriormente, con un compuesto de la Formula (4) por 1, 2, o 3 sustituyentes seleccionados a partir del grupo que consiste en halogeno, alquilon de 1 a 7 átomos de carbono, trifluorometilo, hidroxilo y alcoxilo de 1 a 7 átomos de carbono, y X es halogeno, en la presencia de una base, para formar un compuesto de la Formula 1, y c) opcionalmente, formal un solvato o hidrato deseado de los mismos.
ARP070101533A 2006-04-13 2007-04-11 Compuestos organicos AR060506A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0607532A GB0607532D0 (en) 2006-04-13 2006-04-13 Organic compounds
GB0610244A GB0610244D0 (en) 2006-05-23 2006-05-23 Organic compounds

Publications (1)

Publication Number Publication Date
AR060506A1 true AR060506A1 (es) 2008-06-25

Family

ID=38324102

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101533A AR060506A1 (es) 2006-04-13 2007-04-11 Compuestos organicos

Country Status (29)

Country Link
US (2) US8008479B2 (es)
EP (1) EP2010498B1 (es)
JP (1) JP5208917B2 (es)
KR (1) KR20080108291A (es)
AR (1) AR060506A1 (es)
AT (1) ATE486853T1 (es)
AU (1) AU2007237482B2 (es)
CA (1) CA2645362C (es)
CL (1) CL2007001040A1 (es)
CY (1) CY1111294T1 (es)
DE (1) DE602007010269D1 (es)
DK (1) DK2010498T3 (es)
EC (1) ECSP088820A (es)
GT (1) GT200800209A (es)
HK (1) HK1125640A1 (es)
HR (1) HRP20110045T1 (es)
JO (1) JO2630B1 (es)
MA (1) MA30394B1 (es)
MX (1) MX2008013117A (es)
MY (1) MY145069A (es)
NO (1) NO20084783L (es)
NZ (1) NZ571142A (es)
PE (1) PE20071223A1 (es)
PL (1) PL2010498T3 (es)
PT (1) PT2010498E (es)
RU (1) RU2433122C2 (es)
SI (1) SI2010498T1 (es)
TW (1) TW200815358A (es)
WO (1) WO2007118651A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0515973B8 (pt) 2004-10-12 2021-07-27 Fmc Biopolymer As kit para produzir um gel de alginato, composição para preparar um gel e uso
BRPI0615973A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc novos derivados de benzo [d] [1,3] - dioxol
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8013007B2 (en) 2007-02-26 2011-09-06 Concert Pharmaceuticals, Inc. Alpha 1A-adrenoceptor antagonists
US7943620B2 (en) 2007-03-07 2011-05-17 Concert Pharmaceuticals, Inc. Anti-anginal compounds
WO2008115442A1 (en) 2007-03-16 2008-09-25 Concert Pharmceuticals, Inc. Inhibitors of cholesterol ester transfer protein
WO2008128166A1 (en) 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US8349817B2 (en) 2007-04-25 2013-01-08 Concert Pharmaceuticals, Inc. Analogues of cilostazol
US20090042842A1 (en) 2007-04-25 2009-02-12 Concert Pharmaceuticals, Inc. Analogues of cilostazol
PL2522668T3 (pl) 2007-05-01 2015-07-31 Concert Pharmaceuticals Inc Związki morfinanu
HUE029782T2 (en) 2007-05-01 2017-04-28 Concert Pharmaceuticals Inc morphinan
US7820666B2 (en) 2007-05-08 2010-10-26 Concert Pharmaceuticals, Inc. Tetrahydrotriazolopyrazine derivatives and uses thereof
WO2008156632A1 (en) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
CA2702317A1 (en) 2007-07-09 2009-01-15 Concert Pharmaceuticals, Inc. Novel pyrimidinecarboxamide derivatives
CN101821260B (zh) 2007-08-14 2013-07-31 康塞特医药品有限公司 取代的噁唑烷酮衍生物
AU2008296975B2 (en) 2007-08-28 2014-07-24 Fmc Corporation Delayed self-gelling alginate systems and uses thereof
EP2197847B1 (en) 2007-09-12 2012-11-07 Concert Pharmaceuticals Inc. Deuterated 4 -oxoquinoline derivative for the treatment of hiv infection
CN101855218A (zh) 2007-09-13 2010-10-06 康塞特医药品有限公司 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
WO2009079637A1 (en) 2007-12-18 2009-06-25 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
US7855204B2 (en) 2008-01-22 2010-12-21 Concert Pharmaceuticals Inc. Derivatives of gefitinib
WO2009094210A1 (en) 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Vandetanib derivatives
EP2265334A2 (en) 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8367674B2 (en) 2008-04-17 2013-02-05 Concert Pharmaceuticals, Inc. Piperazine derivatives
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
CA2735549A1 (en) 2008-08-29 2010-03-04 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
EP2334621A1 (en) 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
DK2418211T3 (en) 2008-09-19 2016-06-27 Concert Pharmaceuticals Inc DEUTERATED MORPHINAN COMPOUNDS
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP5425229B2 (ja) * 2009-02-24 2014-02-26 ノバルティス アーゲー Nk受容体アンタゴニストの使用
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
DE102009001446A1 (de) 2009-03-10 2010-09-23 Evonik Rohmax Additives Gmbh Verwendung von Kammpolymeren als Antifatigue-Additive
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
WO2010108103A1 (en) * 2009-03-19 2010-09-23 Concert Pharmaceuticals, Inc. Azepan-2-one derivatives
WO2010124046A1 (en) 2009-04-23 2010-10-28 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
WO2010135579A1 (en) 2009-05-22 2010-11-25 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
EP2443089B1 (en) 2009-06-18 2014-03-05 Concert Pharmaceuticals Inc. Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
EP2464355A4 (en) 2009-08-14 2013-01-02 Concert Pharmaceuticals Inc SUBSTITUTED TRIAZOLPHTHALAZINE DERIVATIVES
IN2012DN01642A (es) 2009-09-02 2015-06-05 Concert Pharmaceuticals Inc
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US8471034B2 (en) 2009-11-18 2013-06-25 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
DE102010001040A1 (de) 2010-01-20 2011-07-21 Evonik RohMax Additives GmbH, 64293 (Meth)acrylat-Polymere zur Verbesserung des Viskositätsindexes
EP2542534A1 (en) 2010-03-02 2013-01-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US9226801B2 (en) * 2010-03-08 2016-01-05 Ibur, Llc Custom linkable imaging and multifunctional tray
WO2011116066A1 (en) 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
WO2012031073A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031072A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
KR101976218B1 (ko) 2011-02-14 2019-05-07 콘서트 파마슈티컬즈, 인크. 4-히드록시부티르산 중수소화 유사체
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
US8889687B2 (en) 2011-03-04 2014-11-18 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CA2869874A1 (en) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
US20150197525A1 (en) 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US9181190B2 (en) 2012-07-04 2015-11-10 Concert Pharmaceuticals, Inc. Deuterated vercirnon
CA2908929C (en) 2012-07-12 2021-01-26 Concert Pharmaceuticals, Inc. Deuterated idebenone
AU2013296627C9 (en) 2012-07-30 2018-03-22 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
WO2014028756A1 (en) 2012-08-17 2014-02-20 Concert Pharmaceuticals, Inc. Deuterated baricitinib
JP2015534989A (ja) 2012-10-22 2015-12-07 コンサート ファーマシューティカルズ インコーポレイテッド {s−3−(4−アミノ−1−オキソ−イソインドリン−2−イル)(ピペリジン−3,4,4,5,5−d5)−2,6−ジオン}の固体形態
ES2672468T3 (es) 2013-01-09 2018-06-14 Concert Pharmaceuticals Inc. Momelotinib deuterado
EP2968268B1 (en) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
CN106459056A (zh) 2014-02-10 2017-02-22 康塞特医药品公司 经取代的三唑苯二氮卓
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
US10759721B2 (en) 2015-09-25 2020-09-01 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR potentiators
US11267777B2 (en) 2015-11-19 2022-03-08 Concert Pharmaceuticals, Inc. Deuterated EPI-743
EP3416629A4 (en) 2016-02-16 2019-08-07 CoNCERT Pharmaceuticals, Inc. DEUTERATED GFT-505
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
CA3082444A1 (en) 2017-12-01 2019-06-06 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026183A1 (en) * 1995-02-22 1996-08-29 Novartis Ag 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
MY132550A (en) 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB0010958D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PL2010498T3 (pl) 2011-04-29
SI2010498T1 (sl) 2011-03-31
AU2007237482B2 (en) 2011-03-17
RU2433122C2 (ru) 2011-11-10
MX2008013117A (es) 2008-10-21
KR20080108291A (ko) 2008-12-12
PT2010498E (pt) 2011-02-08
CA2645362A1 (en) 2007-10-25
TW200815358A (en) 2008-04-01
MA30394B1 (fr) 2009-05-04
EP2010498B1 (en) 2010-11-03
DE602007010269D1 (de) 2010-12-16
NZ571142A (en) 2011-02-25
AU2007237482A1 (en) 2007-10-25
HRP20110045T1 (hr) 2011-02-28
MY145069A (en) 2011-12-15
JP5208917B2 (ja) 2013-06-12
JO2630B1 (en) 2012-06-17
HK1125640A1 (en) 2009-08-14
JP2009533369A (ja) 2009-09-17
GT200800209A (es) 2008-12-15
US8008479B2 (en) 2011-08-30
EP2010498A1 (en) 2009-01-07
DK2010498T3 (da) 2011-02-14
CL2007001040A1 (es) 2008-03-14
CA2645362C (en) 2013-07-16
RU2008145102A (ru) 2010-05-27
CY1111294T1 (el) 2015-08-05
US20110282053A1 (en) 2011-11-17
NO20084783L (no) 2008-11-12
PE20071223A1 (es) 2008-01-22
ATE486853T1 (de) 2010-11-15
WO2007118651A1 (en) 2007-10-25
ECSP088820A (es) 2008-11-27
US20090137797A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
AR060506A1 (es) Compuestos organicos
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
CY1119101T1 (el) Ναφθαλινο-ισοξαζολινες ως παραγοντες καταπολεμισης ασπονδυλων παρασιτων
BR112013009935B8 (pt) Compostos
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
BR112012014858A2 (pt) agente antiplaqueta
PE20130155A1 (es) Derivados de ariletinilo
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
CU20110052A7 (es) Compuestos orgánicos
PE20121159A1 (es) DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR
CO6362009A2 (es) Derivados de morfolinopurina
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
UY30045A1 (es) Derivados de pirimidina
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
AR073130A1 (es) Derivados de 5-bencil-4-azolilmetil-4-espiro [2.4] heptanol, metodos para producir los mismos y agentes agrohorticolas y agentes para proteger material industrial que los contienen.
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
AR079316A1 (es) Derivado de azol, compuestos intermedios para obtenerlo, metodos para producirlos y agente agro- horticola o agente de proteccion de material industrial que lo comprende
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
BR112013008675A2 (pt) métodos e composições para o tratamento de diabetes e dislipidemia
CR10780A (es) Inhibidores de cinasa
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
AR062769A1 (es) Derivados de 5- fenil- nicotilamida
AR060962A1 (es) Proceso de preparacion de derivados de quinazolina e intermediarios de sintesis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal